Answers are grounded in this paper and cite their sources.
The analysis demonstrated that universal prophylaxis strategy with nirsevimab would significantly reduce the health and economic burden associated with RSV among infants in Japan. At the assumed price, nirsevimab can provide a cost-effective prophylaxis option against RSV infection in an all-infant population not limited to infants born prematurely or with high risk.
No takes yet. Share an insight, caveat, or question.
Noto et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: